Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

bluebird bio, Inc. - Common Stock (NQ:BLUE)

4.970 UNCHANGED
Last Price Updated: 4:00 PM EDT, May 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about bluebird bio, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
News headline image
Long-Term Data Presented at ASH Support beti-cel as a Potentially Curative Gene Therapy for β-Thalassemia Patients Who Require Regular Transfusions Through Achievement of Durable Transfusion Independence and Normal or Near-Normal Adult Hb Levels
From bluebird bio, Inc.
Via Business Wire
News headline image
Long-term Follow-up Data From bluebird’s Gene Therapy Program in Sickle Cell Disease Support Durable, Potentially Curative Benefits Through Stable Production of Anti-Sickling Adult Hemoglobin and Resolution of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
News headline image
FDA Approves First Gene-Editing Cell Therapy For Sickle Cell Disease, An Inherited Blood Disorder ↗
The FDA has approved Casgevy and Lyfgenia, representing the first cell-based gene therapies for sickle cell disease in patients 12 y 
Via Benzinga
News headline image
What's Going On With Bluebird Bio Stock? ↗
Bluebird Bio, Inc. 
Via Benzinga
News headline image
2 Biotech Stocks That Could Soar in December ↗
These two biotechs have important catalysts coming up in December. 
Via The Motley Fool
News headline image
Is Bluebird Bio Stock a Buy? ↗
This biotech looks cheap, but is it a value trap? 
Via The Motley Fool
News headline image
bluebird bio Details Plans for the Commercial Launch of LYFGENIA™ Gene Therapy for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio Announces FDA Approval of LYFGENIA™ (lovotibeglogene autotemcel) for Patients Ages 12 and Older with Sickle Cell Disease and a History of Vaso-Occlusive Events
From bluebird bio, Inc.
Via Business Wire
News headline image
Torrid Reports Upbeat Results, Joins MBIA, Virco Mfg. And Other Big Stocks Moving Higher On Friday ↗
U.S. stocks traded mostly higher, with the Dow Jones index gaining more than 40 points on Friday. 
Via Benzinga
Topics Stocks
News headline image
Where Will Bluebird Bio Be in 1 Year? ↗
Things could get better for the biotech, but they could also get worse. 
Via The Motley Fool
News headline image
These 2 Stocks Could Be About to Soar: Are They Buys? ↗
One thing is for certain -- both of these companies are innovators. 
Via The Motley Fool
News headline image
If You Can Only Buy One Biotech Stock in December, It Better Be One of These 3 Names ↗
As we head into December 2023, some of the hottest investment opportunities can be found in these biotech stocks. 
Via InvestorPlace
News headline image
Why FLJ Group Shares Are Trading Higher By Around 96%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Shares of FLJ Group Limited (NASDAQ: FLJ) shares jumped during Friday’s session after the company announced it entered into a definitive agreement to acquire Alpha Mind Technology. FLJ Group shares... 
Via Benzinga
News headline image
2 Beaten-Down Growth Stocks That Could Rocket 42% to 67% Higher, According to Wall Street ↗
Investment bank analysts are pounding the table on these stocks, but are they right for your portfolio? 
Via The Motley Fool
News headline image
Bluebird Bio To Rally Around 267%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page 
Via Benzinga
News headline image
Why Bluebird Bio Stock Soared 7% Higher on Tuesday ↗
The company posted some encouraging numbers and said it had sufficient resources to take care of financial obligations through the second quarter of 2024. 
Via The Motley Fool
News headline image
bluebird bio Reports Third Quarter 2023 Financial Results and Highlights Operational Progress
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio to Present New and Updated Data from Gene Therapy Programs in Sickle Cell Disease and Beta-Thalassemia at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
From bluebird bio, Inc.
Via Business Wire
News headline image
Gene Therapy Could Be On the Cusp of a Major Breakthrough, but Investors May Have to Remain Patient ↗
This gene-editing pioneer could make history this week. But shareholders should remain focused on the long term. 
Via The Motley Fool
News headline image
bluebird bio Enters into Advance Agreement to Sell Priority Review Voucher, if Granted, for $103 Million
From bluebird bio, Inc.
Via Business Wire
News headline image
bluebird bio to Host Third Quarter 2023 Financial Results Conference Call
From bluebird bio, Inc.
Via Business Wire
News headline image
Cautious Optimism For Bluebird Bio's Sickle Cell Therapy: Analyst Sees Financial Challenges ↗
Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (NASDAQ: BLUE), saying sickle cell disorder (SCD) has been a hotbed of development for genetic medicines as the company's lovo-cel marches... 
Via Benzinga
News headline image
Editas Medicine Has To Navigate Sickle Cell Therapy Competition: Analyst ↗
Cantor Fitzgerald has downgraded Editas Medicine Inc (NASDAQ: EDIT) to Neutral from Overw 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023 ↗
 
Via Benzinga
News headline image
Cathie Wood Is Buying This Growth Stock Hand Over Fist Lately. Should You Follow Her Lead? ↗
The Internet's most famous innovation-focused investor is excited about this company's innovative approach to editing the human genome. 
Via The Motley Fool
News headline image
Fisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesday ↗
U.S. stocks traded lower, with the Dow Jones falling around 200 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Topics Stocks
News headline image
Are Gene Therapy Stocks The Market's Next Big Winners?
Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price. 
Via MarketBeat
Topics Artificial Intelligence
News headline image
Better Growth Stock: CRISPR Therapeutics vs. Bluebird Bio ↗
These two biotechs have a lot in common, but one is much better capitalized. 
Via The Motley Fool
News headline image
1 Huge Risk That Gene-Editing Stock Investors Desperately Need to Know ↗
Good medicines aren't always good business. 
Via The Motley Fool
News headline image
Have Million-Dollar Gene Therapies Finally Reached An Inflection Point? ↗
Gene therapies are clearing the FDA and reaching seriously ill patients. They could cost millions. 
Via Investor's Business Daily
< Previous 1 2
...
7 8 9 10 11 12 13 14 15
...
22 23 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.